CA2590735C - Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy}-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof - Google Patents

Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy}-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof Download PDF

Info

Publication number
CA2590735C
CA2590735C CA002590735A CA2590735A CA2590735C CA 2590735 C CA2590735 C CA 2590735C CA 002590735 A CA002590735 A CA 002590735A CA 2590735 A CA2590735 A CA 2590735A CA 2590735 C CA2590735 C CA 2590735C
Authority
CA
Canada
Prior art keywords
azd0530
compound
solvent
conveniently
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002590735A
Other languages
English (en)
French (fr)
Other versions
CA2590735A1 (en
Inventor
James Gair Ford
James Francis Mccabe
Anne O'kearney-Mcmullan
Philip O'keefe
Simon Mark Pointon
Lyn Powell
Mark Purdie
Jane Withnall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CA002675642A priority Critical patent/CA2675642A1/en
Publication of CA2590735A1 publication Critical patent/CA2590735A1/en
Application granted granted Critical
Publication of CA2590735C publication Critical patent/CA2590735C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002590735A 2004-12-17 2005-12-14 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy}-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof Expired - Lifetime CA2590735C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002675642A CA2675642A1 (en) 2004-12-17 2005-12-14 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methyl piperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0427697.8 2004-12-17
GBGB0427697.8A GB0427697D0 (en) 2004-12-17 2004-12-17 Chemical process
PCT/GB2005/004807 WO2006064217A2 (en) 2004-12-17 2005-12-14 PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002675642A Division CA2675642A1 (en) 2004-12-17 2005-12-14 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methyl piperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof

Publications (2)

Publication Number Publication Date
CA2590735A1 CA2590735A1 (en) 2006-06-22
CA2590735C true CA2590735C (en) 2009-11-10

Family

ID=34090249

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002590735A Expired - Lifetime CA2590735C (en) 2004-12-17 2005-12-14 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl) ethoxy}-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof
CA002675642A Abandoned CA2675642A1 (en) 2004-12-17 2005-12-14 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methyl piperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002675642A Abandoned CA2675642A1 (en) 2004-12-17 2005-12-14 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methyl piperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof

Country Status (16)

Country Link
US (1) US8304417B2 (https=)
EP (1) EP1871769B1 (https=)
JP (2) JP5161584B2 (https=)
KR (6) KR20080094847A (https=)
CN (1) CN101115744B (https=)
AU (2) AU2005315458B2 (https=)
BR (1) BRPI0519085A2 (https=)
CA (2) CA2590735C (https=)
ES (1) ES2622480T3 (https=)
GB (1) GB0427697D0 (https=)
IL (1) IL183525A0 (https=)
MX (1) MX2007007210A (https=)
NO (1) NO20072755L (https=)
NZ (1) NZ555468A (https=)
WO (1) WO2006064217A2 (https=)
ZA (1) ZA200704532B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
CN103275072B (zh) * 2013-05-22 2016-01-20 苏州明锐医药科技有限公司 塞卡替尼的制备方法
US11241434B2 (en) 2013-06-13 2022-02-08 Yale Uninversity Compositions and methods for improving cognition in a subject
US10660957B2 (en) * 2013-06-13 2020-05-26 Yale University Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US10369152B2 (en) 2015-02-13 2019-08-06 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
PT3930715T (pt) 2019-02-27 2024-08-02 Astrazeneca Ab Saracatinib para uso no tratamento de fibrose pulmonar idiopática
CN116332789A (zh) * 2023-03-10 2023-06-27 上海康鹏科技股份有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
CA2419301C (en) 2000-08-21 2009-12-08 Astrazeneca Ab Quinazoline derivatives
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0307333D0 (en) 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
ZA200704532B (en) 2008-07-30
CN101115744A (zh) 2008-01-30
KR20080094847A (ko) 2008-10-24
US8304417B2 (en) 2012-11-06
EP1871769A2 (en) 2008-01-02
KR20080094846A (ko) 2008-10-24
KR20110114727A (ko) 2011-10-19
US20090099196A1 (en) 2009-04-16
CA2675642A1 (en) 2006-06-22
EP1871769B1 (en) 2017-02-22
JP5161584B2 (ja) 2013-03-13
KR20080094849A (ko) 2008-10-24
AU2005315458B2 (en) 2009-03-12
AU2005315458A1 (en) 2006-06-22
BRPI0519085A2 (pt) 2008-12-23
NZ555468A (en) 2010-12-24
WO2006064217A3 (en) 2006-12-21
WO2006064217A2 (en) 2006-06-22
WO2006064217A8 (en) 2007-07-05
MX2007007210A (es) 2007-11-07
IL183525A0 (en) 2007-09-20
AU2009200622A1 (en) 2009-03-12
KR20070090004A (ko) 2007-09-04
JP2008524183A (ja) 2008-07-10
CA2590735A1 (en) 2006-06-22
CN101115744B (zh) 2012-02-01
JP2009143920A (ja) 2009-07-02
NO20072755L (no) 2007-07-02
ES2622480T3 (es) 2017-07-06
KR20080094848A (ko) 2008-10-24
GB0427697D0 (en) 2005-01-19

Similar Documents

Publication Publication Date Title
EP1480650B1 (en) Novel crystalline forms of the anti-cancer compound zd1839
AU2009200622A1 (en) Process for the preparation of 4-(6-chloro-2, 3-methylenedioxyanilino)-7-(2-(4-methylpiperazin-1-yl) ethoxy)-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof
ZA200406729B (en) Novel crystalline forms of the anti-cancer compound ZD 1839.
TW201512204A (zh) 埃克替尼磷酸鹽的新晶型及其用途
WO2023131234A1 (en) Crystalline forms of an atr inhibitor
HK1070582B (en) Novel crystalline forms of the anti-cancer compound zd1839
WO2018054359A1 (zh) 一种喹唑啉衍生物的盐、其制备方法及应用

Legal Events

Date Code Title Description
EEER Examination request